B-Cell Hematologic Malignancy Vaccination Registry
The goal of this study is to develop a vaccination registry system for Aurora Health Care patients newly diagnosed with MM and other B-Cell Hematologic Malignancies in order to prospectively characterize vaccination history and outcomes such as infection in these patients at Aurora Health Care. Additionally hospitalization rates, cost analysis, infection (influenza, pneumonia, other) related to vaccination in this patient population will be evaluated.
Checked against the public recordLast updated Oct 3, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Wake Forest University Health Sciences
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Adult patients at Aurora Health Care who are newly diagnosed with: * Monoclonal gammopathy of undetermined significance (MGUS), * Smoldering multiple myeloma (SMM), * Multiple myeloma (MM), * Waldenstroms Macroglobulinemia (WM), * Monoclonal B-cell lymphocytosis (MBL), * Chronic lymphocytic leukemia (CLL), or * B-Cell Non-Hodgkin lymphoma (NHL). Exclusion Criteria: * none
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Aurora Health CareMilwaukee, Wisconsin
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 3, 2024. Always confirm current availability with the study team.